These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 34720008)
1. Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline. Xu J; Ashjian E J Pharm Pract; 2023 Jun; 36(3):650-661. PubMed ID: 34720008 [TBL] [Abstract][Full Text] [Related]
2. New therapeutic approaches for the treatment of hypertriglyceridemia. Gouni-Berthold I; Schwarz J Herz; 2022 Jun; 47(3):220-227. PubMed ID: 35451595 [TBL] [Abstract][Full Text] [Related]
4. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118 [TBL] [Abstract][Full Text] [Related]
9. Targeting apoC-III and ANGPTL3 in the treatment of hypertriglyceridemia. Nurmohamed NS; Dallinga-Thie GM; Stroes ESG Expert Rev Cardiovasc Ther; 2020 Jun; 18(6):355-361. PubMed ID: 32511037 [TBL] [Abstract][Full Text] [Related]
10. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Ito MK Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750 [TBL] [Abstract][Full Text] [Related]
11. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study. Hussain A; Sun C; Selvin E; Nambi V; Coresh J; Jia X; Ballantyne CM; Hoogeveen RC Eur J Prev Cardiol; 2022 Mar; 29(2):e53-e64. PubMed ID: 33580780 [TBL] [Abstract][Full Text] [Related]
12. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. Orringer CE; Jacobson TA; Maki KC J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586 [TBL] [Abstract][Full Text] [Related]
13. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease? Reeskamp LF; Tromp TR; Stroes ESG Curr Opin Lipidol; 2020 Jun; 31(3):140-146. PubMed ID: 32324598 [TBL] [Abstract][Full Text] [Related]
14. Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art? Florentin M; Kostapanos MS; Anagnostis P; Liamis G Expert Opin Pharmacother; 2020 Jan; 21(1):107-120. PubMed ID: 31738617 [No Abstract] [Full Text] [Related]
15. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors. Spagnuolo CM; Hegele RA Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828 [TBL] [Abstract][Full Text] [Related]
16. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses? Chan DC; Watts GF Curr Opin Lipidol; 2024 Jun; 35(3):101-109. PubMed ID: 38372218 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment. Picard F; Steg PG Curr Atheroscler Rep; 2021 Mar; 23(6):27. PubMed ID: 33788024 [TBL] [Abstract][Full Text] [Related]
18. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. Michaeli DT; Michaeli JC; Albers S; Boch T; Michaeli T Am J Cardiovasc Drugs; 2023 Sep; 23(5):477-495. PubMed ID: 37486464 [TBL] [Abstract][Full Text] [Related]
19. Investigational drugs in development for hypertriglyceridemia: a coming-of-age story. Rhainds D; Brodeur MR; Tardif JC Expert Opin Investig Drugs; 2019 Dec; 28(12):1059-1079. PubMed ID: 31752565 [No Abstract] [Full Text] [Related]